Home / Health / New Brain Health Index to Track Cognitive Decline
New Brain Health Index to Track Cognitive Decline
26 Mar
Summary
- Brain Health Index will track disease and treatment response.
- Collaboration aims to advance care models for cognitive decline.
- Spectris technology will be combined with Ochsner's clinical infrastructure.
A new Brain Health Collaboratory has been established through a partnership between Ochsner Health and Cognito Therapeutics. This initiative focuses on advancing care models for cognitive decline and Alzheimer's disease, particularly in the Gulf South region. The Collaboratory aims to develop a Brain Health Index framework to meticulously track disease progression, cognitive health, and patient response to treatments within clinical settings.
The partnership integrates Cognito Therapeutics' investigational Spectris technology platform with Ochsner Health's robust clinical infrastructure. This combination will facilitate the exploration of innovative brain health approaches for both urban and rural populations. Ochsner's Neuroscience Institute, serving a vast area from Houston to Atlanta, will be central to this effort, further enhanced by a new 132,000 sq ft facility dedicated to neurosciences, expected to open late this year.
The Brain Health Collaboratory plans to assess the integration of Spectris therapy into existing healthcare models for cognitive decline. A key objective is to evaluate the clinical and economic impact of non-invasive neuromodulation therapies within value-based care frameworks. This builds upon Cognito Therapeutics' prior collaboration with West Virginia University Rockefeller Neuroscience Institute.
